Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › mogamulizumab

mogamulizumab

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of mogamulizumab

3 trials tracked of mogamulizumab.

3Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 1 Phase 1 2
  1. Phase 2 Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma Completed
  2. Phase 1 Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer Completed
  3. Phase 1 Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome Completed

Showing the 3 most-cited and recently-updated of 3 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Review summarizes molecular pathways and treatment options for Adult T-cell leukemia/lymphoma
Oncology Sys. Review
Review summarizes molecular pathways and treatment options for Adult T-cell leukemia/lymphoma What helps patients with a rare, aggressive blood cancer?
A systematic review summarizes the molecular pathogenesis and treatment landscape for Adult T-cell leukemia/lymphoma (ATLL).
For patients with rare, aggressive Adult T-cell leukemia/lymphoma, a drug called mogamulizumab shows promise when standard treatments fail.
Frontiers Apr 2, 2026